Health Canada generic backlog tops 500 files, with seven semaglutide submissions waiting

The Canadian Generic Pharmaceutical Association says more than 500 generic drug submissions are sitting at Health Canada, including seven for generic semaglutide ^[1]. The industry group said more than 100 of those files are formally backlogged ^[1].

Two generic semaglutide injections have already been authorized in Canada, one from India-based Dr. Reddy's Laboratories and one from Canadian manufacturer Apotex ^[1][2]. The Dr. Reddy's product reached Canadian pharmacies on May 15, 2026, while Apotex had not announced a release date ^[2]. Seven further semaglutide applications were still waiting on decisions ^[1].

Public trackers do not line up exactly. A tracker note lists three of nine generic semaglutide products as approved by Health Canada ^[1], while a separate article describes two authorized injections and seven applications under review ^[2]. Health Canada's Drug Product Database lists Aspen-Semaglutide and Sevmia as approved with no market date as of July 28, 2026 ^[1].

The queue matters because Canadian generic prices are tied to how many manufacturers are on the market. Mina Tadrous, a pharmacist and drug policy researcher at the University of Toronto, told CBC News that with one generic, prices fall to 75% of the brand list price; with two, to 50%; and with three or more, to 35% ^[2]. Tadrous estimated to The BMJ that once three generics are on the market, out-of-pocket costs should reach about C$100 per month ^[2]. Brand-name Ozempic prices tracked in Canada range from C$86.40 to C$663, and Wegovy from C$270 to C$550 ^[2].

Generic semaglutide became possible in Canada after Novo Nordisk stopped paying a C$250 annual patent maintenance fee starting in 2018, and after a separate regulatory approval requirement expired on January 5, 2026 ^[2]. Tahir Amin, chief executive of the Initiative for Medicines, Access & Knowledge, told the BBC that the Canadian patent could have been extended until 2028 but was not renewed ^[2].

Novo Nordisk told the BBC the Canadian situation is "a localized situation based on our specific patent timelines and regulatory environment and does not reflect the situation in the United States, where exclusivity remains intact" ^[2]. The company retains semaglutide patent protection in the United States until 2032 and in Europe and Japan until 2033 ^[2].

Why it matters for patients

The backlog is mostly a question of timing. Each additional generic semaglutide manufacturer that reaches the Canadian market moves the list price down another step, so the seven pending files sit between today's prices and the lowest tier ^[1][2]. For people in Canada paying cash, that gap is the difference between the current brand-price range and the roughly C$100 monthly figure Tadrous associated with three generics on the market ^[2].

For readers in the United States, the practical effect is limited. Semaglutide patent protection in the US runs to 2032, so no comparable generic path has been reported ^[2]. Novo Nordisk has been offering brand-name discount cards in Canada to close the price gap with generics, and has run advertising there urging patients to ask for brand-name Ozempic ^[2]. Eli Lilly's tirzepatide products, Mounjaro and Zepbound, are projected to overtake semaglutide as the leading GLP-1 products within the next few years, according to The BMJ ^[2].

What happens next

Health Canada has not disclosed decision dates for the remaining semaglutide files ^[1]. Sandoz is targeting the third quarter of 2026 for its own generic semaglutide ^[1]. Novo Nordisk has forecast that its 2026 sales would fall between 5% and 13%, its share price fell 17% on the day the guidance was announced, and chief executive Mike Doustdar described 2026 as reflecting "a year of unprecedented pricing pressure" ^[2].